We intend to leverage the knowledge, expertise, capabilities and deep industry relationships of our management team and board of directors to focus on biotechnology companies with the potential to capitalize on the growing biotechnology sector in North America and the Asia-Pacific region (excluding China, Hong Kong and Macau). We shall not undertake our initial business combination with any company being based in or having the majority of the company’s operations in China (including Hong Kong and Macau). 

We will prioritize targets with a particular focus on the biotechnology sector, where our management team and board of directors have extensive experience.

(Note: Biotech Group Acquisition Corp. cut the size of its SPAC IPO by 25 percent to 7.5 million units, down from 10.0 million units initially, and kept the IPO price at $10.00 per unit, according to an S-1/A filing dated May 25, 2022.)